Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatuline Autogel in Active Thyroid-associated Ophthalmopathy
NCT00288522Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jan 2006
- Primary completion
- Apr 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lanreotide in thyroid associated ophthalmopathy (TAO), sponsored by Ipsen. Started Jan 2006; status: terminated.
02
Drugs
lanreotide
03
Conditions
thyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT00288522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00288522.